Novel insights on m\(^6\)A RNA methylation in tumorigenesis: a double-edged sword

Shaoyun Wang\(^\dagger\), Peiwei Chai\(^\dagger\), Ruobing Jia\(^\dagger\) and Renbing Jia \(^*\)

Abstract

N6-methyladenosine (m\(^6\)A), the most prevalent modification of mammalian RNA, has received increasing attention. Although m\(^6\)A has been shown to be associated with biological activities, such as spermatogenesis modulation, cell spermatogenesis and pluripotency, Drosophila sex determination, and the control of T cell homeostasis and response to heat shock, little is known about its roles in cancer biology and cancer stem cells. Recent articles have noted that some genes have abnormal m\(^6\)A expression after tumorigenesis, including genes ABS2, RARA, MYB, MYC, ADAM19 and FOX1. Abnormal changes in the m\(^6\)A levels of these genes are closely related to tumour occurrence and development. In this review, we summarized the ‘dual edge weapon’ role of RNA methylation in the tumorigenesis. We discussed RNA methylation could lead to not only tumour progression but also tumour suppression. Moreover, we clarified that the abnormal changes in the m\(^6\)A enrichment of specific loci contribute to tumour occurrence and development, thereby representing a novel anti-cancer strategy by restoration to balanced RNA methylation in tumour cells.

Keywords: RNA methylation, m\(^6\)A, Tumorigenesis

Background

Approximately 100 different post-transcriptional chemical modifications are present in RNA among all living organisms [1]. N6-methyladenosine (m\(^6\)A), one such modification, was identified in the 1970s as the most abundant internal chemical modification in eukaryotic mRNA [2]. Approximately 0.1–0.4% of adenosine nucleotides in isolated mammalian RNA are chemically modified [3]. Extensive m\(^6\)A modifications are present in the RNA of plants and vertebrates, and these modifications also occur in the RNA of single-celled organisms, such as bacteria and yeast [2, 4–7]. m\(^6\)A-based modifications occur at a consensus motif, RRM\(^6\)ACH([G/A/U][G > A]m\(^6\) AC[U > A > C]) [8] (Fig. 1). Furthermore, m\(^6\)A is mainly concentrated on stop codons, in 3′ untranslated regions (3′UTRs), and within internal long exons, based on detection with m\(^6\)A-specific antibodies and high-throughput sequencing [9]. A multicomponent methyltransferase complex catalysing m\(^6\)A formation was first reported in 1994 [10]. Subsequently, methyltransferase-like 3 (METTL3), which functions as an S-adenosyl methionine-binding protein, was the first protein found to possess methyltransferase capacity [11]. Later, other m\(^6\)A methyltransferase components were gradually discovered in mammals, including Wilms tumour 1-associated protein (WTAP), methyltransferase-like protein 14 (METTL14), RNA binding motif protein 15 (RBM15), KIAA1429 and zinc finger CCCH-type containing 13 (ZC3H13) (‘writers’) [12–15]. METTL3 and METTL14 form a stable complex in mammalian cells that accurately localizes at methylation sites by associating with WTAP [12]. The catalytic methyltransfer activity of METTL14 is approximately 10 times that of METTL3, but WTAP has no catalytic methyltransfer activity [12]. Recently, methyltransferase-like protein 16 (METTL16) was confirmed to be a m\(^6\)A methyltransferase that methylates U6 spliceosomal RNA and interacts with the 3′-terminal RNA triple helix of metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) [16]. In 2011, the first demethylase fat mass and obesity-associated protein (FTO) was identified, demonstrating that m\(^6\)A modifications on mRNA are reversible and dynamic [17]. FTO and alkB homologue 5 (ALKBH5) function as two kinds of demethylases (‘erasers’) and may target distinct sets of target mRNAs [18, 19]. Members of the YT521-B homology (YTH) domain family of proteins (YTHDF1, YTHDF2, YTHDF3, YTHDC1 and YTHDC2)
YTHDC2) have a conserved m^6A-binding pocket and directly read m^6A-mediated physiological effects [9, 20–25]. Heterogeneous nuclear ribonucleoprotein (HNRNP) proteins HNRNPA2B1 and HNRNPC selectively bind m^6A-containing mRNAs to respond to physiological effects [26, 27]. These proteins influence mRNA processing by impacting functions such as mRNA splicing, export, and translation initiation [24, 26, 28]. Recently, insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs; including IGF2BP1/2/3) were found to recognize m^6A RNA modifications, functioning as a distinct family of m^6A readers [29]. In addition, fragile X mental retardation 1 (FMR1) and leucine rich pentatricopeptide repeat containing (LRPPRC) read m^6A modifications on target loci and influence RNA behaviour [30] (Fig. 1).

N^6-methyladenosine represents one of the most common RNA modifications in eukaryotes, regulating RNA behaviours such as splicing or the ability to code diverse proteins [9, 20–25]. Recently, aberrant m^6A modification in the large internal exon of a tumour suppressor was shown to give rise to premature polyadenylation, leading to membrane associated guanylate kinase (MAGI3) inactivation [31]. In addition, m^6A regulates other forms of RNA modification. There is a significant negative correlation between two distinct and abundant RNA modifications, m^6A and adenosine-to-inosine (A-to-I), suggesting a previously underappreciated interplay between them [32]. N^6-methyladenosine also affects the function of Long non-coding RNA (LincRNA). LincRNA 1281 is required for proper differentiation of mouse embryonic stem cells, and this critical function relies on sufficient m^6A modification [33]. m^6A may also play a functional role by regulating histones and DNA. The homeostatic regulation of S-adenosylmethionine (SAM) synthesis in mammalian cells involves dynamic m^6A modifications on the 3'UTR of methionine adenosyltransferase 2A (MAT2A) [34]. In this review, we will briefly introduce physiological activities related to m^6A modification. Then, we will describe in detail the ability of m^6A modifications, functioning as a double-edged sword, to play a regulatory role in tumorigenesis and development.

**Physiologic functions of m^6A modifications**

The dynamic reversibility of m^6A methylation suggests that it plays an important role in physiological processes. Studies have revealed that m^6A modifications on...
mRNAs or non-coding RNAs play important roles in spermatogenesis, T cell homeostasis, \textit{Drosophila} sex determination, heat shock responses, pluripotency and reprogramming, as well as other processes [27, 35–39] (Table 1).

\textbf{m}^6\textbf{A} \textbf{modulates spermatogenesis}

The process by which diploid spermatogonial stem cells (SSCs) produce haploid spermatozoa is called spermatogenesis [35]. m\(^6\)A is reportedly present on the key regulatory factors of SSCs/progenitor cells, such as \textit{Plzf, Id4}, \textit{Dnmt3b}, and \textit{Sohlh2}, which control the timing of transcript translation to coordinate normal protein generation, and this modification is essential for mammalian spermatogenesis [39]. m\(^6\)A deletion resulted in the dysregulation of proliferation and differentiation factors of SSC/progenitor cells and SSC depletion [39].

\textbf{m}^6\textbf{A} \textbf{influences T cell homeostasis}

Peripheral T cells are subject to complex and rigorous regulation, and the interleukin 7(II-7)/signal transducer and activator of transcription 5(STAT5) signal axis is highly significant for maintaining naive T cell homeostasis and survival [36]. Decreased levels of m\(^6\)A modification on the mRNAs of suppressor of cytokine signalling (SOCS) family genes have been reported to slow mRNA decay and increase protein expression levels (SOCS1, SOCS3 and CISH) in naive T cells [40]. Overexpression of SOCS1, SOCS3 and CISH leads to the inhibition of the downstream signal IL-7/STAT5, preventing naive T cell proliferation and differentiation while maintaining T cell survival [40]. Thus, m\(^6\)A modifications are known to play an important role in T cell homeostasis.

\textbf{m}^6\textbf{A} \textbf{is involved in \textit{Drosophila} sex determination}

Mammalian m\(^6\)A enzyme complexes include including WTAP, METTL14, RBM15, KIAA1429 and ZC3H13 [12–15]. The corresponding m\(^6\)A methylation enzyme analogues in \textit{Drosophila} include inducer of meiosis 4 (Ime4), karyogamy protein 4 (KAR4), female-lethal(2)dFl(2)d and virilizer(Vir) [11, 12, 41–43]. The m\(^6\)A reader protein YT521-B has been reported to read m\(^6\)A modifications on Sxl to promote Sxl alternative splicing, which determines female physiognomy [38]. The ability of YT521-B to read m\(^6\)A explains the importance of this modification in \textit{Drosophila} sex determination through the selective splicing of Sxl [38].

\textbf{Table 1} \textbf{m}^6\textbf{A} \textbf{chemical modifications affect physiological function}

| Physiological activities | Genes involved | Description | Reference |
|-------------------------|----------------|-------------|-----------|
| Spermatogenesis          | \textit{Plzf, Dnmt3b, Id4} and \textit{Sohlh2} | Deletion of m\(^6\)A results in the dysregulation of spermatogenesis | [39] |
| T cell homeostasis       | \textit{SOCS1, SOCS3} and \textit{CISH} | Decreased m\(^6\)A modification inhibits naive T cell proliferation and differentiation but maintains cell survival | [40] |
| \textit{Drosophila} sex determination | \textit{Sxl} | YT521-B reads the m\(^6\)A modification of Sxl to promote Sxl alternative splicing, which determines female physiognomy | [38] |
| Heat shock response      | \textit{Hsp105} | Under heat shock stress, m\(^6\)A is preferentially deposited at the 5'UTR of new stress-inducible transcripts, such as \textit{Hsp105} (HSPH1), and enhances cap-independent translation initiation | [28] |
| Somatic cell reprogramming and pluripotency of ESCs | \textit{Nanog, Sox2, Klf4 and c-Myc} | High m\(^6\)A modification levels accelerate mRNA degradation of these genes, which damages ESC self-renewal and somatic cell reprogramming | [37] |

\textbf{High levels of m}^6\textbf{A during the heat shock response}

The heat shock response is a complex cellular reaction that causes significant changes in protein translation, folding and degradation, thereby mitigating toxic reactions caused by protein misfolding [44]. m\(^6\)A and the heat shock response are linked because m\(^6\)A is the most abundant mRNA post-transcriptional modification. A new report has revealed that m\(^6\)A is preferentially deposited on the 5'UTR of new stress-inducible transcripts, such as \textit{Hsp105} (HSPH1), under heat shock stress, and that increased levels of m\(^6\)A modification at the 5'UTR can enhance cap-independent translation initiation [28]. Thus, the mechanistic connection between 5'UTR methylation and cap-independent translation reveals links between the heat shock response and m\(^6\)A [28].

\textbf{m}^6\textbf{A} \textbf{influences somatic cell reprogramming and maintains the pluripotency of embryonic stem cells (ESCs)}

Epigenetic and epitranscriptomic networks play important roles in somatic cell reprogramming and the maintenance of ESC pluripotency [37]. A new study has revealed that zinc finger protein 217 (\textit{ZFP217}) activates the transcription of key pluripotency genes and modulates m\(^6\)A deposition on their transcripts [37]. \textit{ZFP217} depletion globally enhances m\(^6\)A modification on \textit{Nanog, Sox2, Klf4} and \textit{c-Myc} mRNAs to accelerate their degradation, thus damaging ESC self-renewal and somatic cell reprogramming [37]. This finding represents strong evidence of the close relationships between m\(^6\)A and
somatic cell reprogramming and the maintenance of ESC pluripotency.

**Aberrant m^6^A modification contributes to diversified tumours**

Given the important role of RNA m^6^A modification in regulating gene expression and various biological processes [2], it is reasonable to speculate that aberrant m^6^A modification plays an important role in human carcinogenesis. However, knowledge of the mechanistic link between m^6^A and human carcinogenesis is rather limited. While investigations addressing this issue are still at an early stage, efforts are underway to explore the biological impacts of m^6^A modifications in cancer. We will summarize recent reports describing our understanding of the biological functions and underlying molecular mechanisms of m^6^A regulatory proteins in various types of cancer and explore new options for cancer treatment (Fig. 2 and Table 2).

**Connection between m^6^A and acute myeloid leukaemia (AML)**

AML is one of the most common haematopoietic malignancies and is associated with a high mortality and distinct genetic and molecular abnormalities that lead to unsatisfactory therapeutic effects [45, 46]. Only a small proportion of patients survive for more than 5 years with standard chemotherapies [45, 46]. Therefore, it is urgent and necessary to explore new treatments for AML based on a deep understanding of the mechanisms of AML occurrence and development.

FTO, an obesity risk-associated gene and the first m^6^A eraser to be identified, has been reported to play an important oncogenic role in haematopoietic cell transformation and AML [17, 47]. FTO levels in certain subtypes of AML (e.g., t(11q23)/MLL-rearranged, t(15;17), FLT3-ITD, and/or NPM1-mutated) are abnormally elevated, which leads to the downregulation of m^6^A levels on the UTRs of ASB2 and RARA [47]. These low levels of m^6^A reduce the mRNA and protein levels of these two genes [47]. FTO is not the only demethylase with a link with AML; METTL14 also plays an important oncogenic role in this disease by regulating its mRNA targets (e.g., MYB, MYC) through m^6^A modifications, which in turn leads to enhanced MYB and MYC expression and ultimately blocks myeloid differentiation [48]. Additionally, a new report has shown that FTO promotes the stability of MYC mRNA by inhibiting YTHDF2-mediated RNA decay.
which is attributed to decreased m\textsuperscript{6}A abundance on the 5′-terminal and internal exons of MYC mRNA, indicating that m\textsuperscript{6}A modifications on different regions of the same mRNA transcript (e.g., MYC) lead to distinct fates [48, 49].

Furthermore, it has been reported that the presence of increased METTL3 levels in AML leads to higher m\textsuperscript{6}A methylation levels of BCL2 and PTEN and promotes the translation of BCL2 and PTEN mRNA, which ultimately leads to tumour formation [50]. Recently, another study revealed that METTL3 binds to the promoter region of SP1 with the aid of transcription factor CEBPZ, which enhances m\textsuperscript{6}A modification of SP1, strengthens SP1 gene expression, and ultimately leads to myeloid leukaemia [51]. In general, changes in m\textsuperscript{6}A modification levels on ASB2, RARA, MYB, BCL2, SP1 and PTEN eventually lead to the occurrence of AML [47–50].

**Aberrant m\textsuperscript{6}A in hepatocellular carcinoma (HCC)**

HCC is a major type of primary liver cancer, accounting for the 5th highest incidence of malignant tumours worldwide and causing more than 700,000 annual deaths [52]. The prevalence of hepatitis B and C viruses in Asia is the main cause of the high incidence of liver cancer in Asia [52]. Effective interventions are lacking, resulting in high HCC mortality due to metastasis and recurrence; thus, a deeper understanding of the molecular mechanism underlying the occurrence and development of HCC is required. Growing evidence suggests that the occurrence of liver cancer is a multistep process involving complex interactions between genetics, epigenetics and transcriptional changes [53]. Previous studies have shown that DNA hypermethylation occurs on CpG islands of the promoter regions of tumour suppressor genes, such as DLC1, TPFI-2, CDKN2A, and PTEN, ultimately affecting tumorigenesis and development [54–56]. It was reported that high levels of the histone methyltransferases EZH2, SUV39H1, SETDB1 and G9a promote the development and metastasis of HCC via epigenetic silencing of critical tumour suppressor genes [57–59]. In general, abnormal epigenetic modifications may be important factors in the development of liver cancer.

Many articles note that the development of liver cancer is associated with abnormal m\textsuperscript{6}A modifications [60, 61]. The high expression of METTL3 in human HCC reportedly leads to increased m\textsuperscript{6}A modification levels on the tumour suppressor SOCS2 [60]. Excessive m\textsuperscript{6}A chemical modification of SOCS2 is read by YTHDF2, which accelerates the degradation of SOCS2 and eventually leads to the occurrence of HCC [60]. Another report has indicated that decreased METTL14 expression reduces m\textsuperscript{6}A modification levels and the expression of microRNA126 (miR126) [61]. Low m\textsuperscript{6}A modification levels on miR126 are recognized by DGC8 and may ultimately promote

### Table 2 Aberrant m\textsuperscript{6}A modification plays an important role in tumorigenesis

| Tumour Type                        | Gene involved | Gene function | Description                                                                 | reference |
|------------------------------------|---------------|---------------|-----------------------------------------------------------------------------|-----------|
| Acute myeloid leukaemia            | ASB2, RARA    | Anti-oncogene  | Elevated FTO leads to low levels of m\textsuperscript{6}A on ASB2 and RARA at UTRs, which reduces the mRNA and protein levels of these two genes | [47]      |
|                                    | MYB, MYC      | Oncogene      | METTL14 enhances m\textsuperscript{6}A modification of MYB and MYC, which in turn leads to overexpression of MYB and MYC | [48]      |
|                                    | BCL2, PTEN    | Oncogene      | Increased METTL3 in AML enhances m\textsuperscript{6}A modification of BCL2 and PTEN, which leads to overexpression of BCL2 and PTEN | [50]      |
|                                    | SP1           | Oncogene      | METTL3 binds to the promoter region of sp1 and enhances m\textsuperscript{6}A modification and gene expression | [51]      |
| Hepatocellular carcinoma           | SOCS2         | Anti-oncogene  | High expression of METTL3 in human HCC leads to high m\textsuperscript{6}A levels on SOCS2, causing the rapid degradation of SOCS2 | [60]      |
|                                    | microRNA126   | Anti-oncogene  | Decreased METTL14 reduces m\textsuperscript{6}A modification levels and the expression of microRNA126 | [61]      |
| Glioblastoma stem cells            | ADAM19        | Oncogene      | Low levels of METTL3 and METTL14 decrease m\textsuperscript{6}A modification of ADAM19, which enhances the expression of ADAM19 | [69]      |
|                                    | FOXM1         | Oncogene      | High levels of ALKBH5 decrease m\textsuperscript{6}A modification levels of FOXM1 and enhance the expression of FOXM1, which ultimately causes glioblastoma | [70]      |
| Breast cancer                      | KLF4, NANOG   | Oncogene      | ZNF217 interacts with METTL3 and inhibits the m\textsuperscript{6}A methylation of KLF4 and NANOG, which ultimately leads to high expression of KLF4 and NANOG | [74]      |
|                                    | HBXIP         | Oncogene      | High levels of METTL3 enhance m\textsuperscript{6}A modification of HBXIP, which accelerates HBXIP expression | [75]      |
|                                    | MAGI3         | Anti-oncogene  | High levels of m\textsuperscript{6}A modification in the large internal exon of MAGI3 promote the occurrence of breast cancer | [31]      |
| Cervical cancer                    | β-catenin     | Anti-oncogene  | Upregulated FTO represses m\textsuperscript{6}A modification of β-catenin and induces chemoradiotherapy resistance | [79]      |
liver carcinogenesis [61]. These articles strongly suggest that abnormal m6A modification plays an important role in the occurrence and development of HCC.

**The foundation role of m6A in glioblastoma stem cells (GSCs)**

Glioblastomas are primary brain tumours with a high degree of malignancy [62]. The median survival time after diagnosis is usually less than 15 months, even if diagnosis is combined with surgical resection, radiotherapy and chemotherapy [62, 63]. GSCs are a group of tumour stem cells with the ability to promote tumour growth and invasion, showing strong resistance to radiotherapy and chemotherapy; these characteristics are the main reasons for the poor prognosis of glioblastoma [64–67]. Therefore, the issue of stem cell resistance should be focused on and addressed to improve therapeutic approaches to glioblastoma [66, 68]. RNA epigenetics has become a rapidly developing field in biology and may be valuable for informing glioblastoma treatment.

A study showed that low levels of METTL3 or METTL14, key components of the RNA methyltransferase complex, lead to decreased m6A modification levels on ADAM19 and the enhanced expression of ADAM19 in GSCs, ultimately causing glioblastoma [69]. Low m6A modification levels on ADAM19 and high mRNA expression levels of ADAM19 may represent a promising target for anti-glioblastoma therapy [69]. Another study revealed that aberrant m6A modifications caused by high levels of ALKBH5, an m6A demethylase, are an obvious physiological abnormality of GSCs [70]. Decreased m6A modification levels of FOXM1 result in enhanced FOXM1 expression levels, which ultimately cause glioblastoma [70]. Aberrant m6A modifications caused by different mechanisms in GSCs strongly suggest that this modification is related to the occurrence and development of glioblastoma.

**Abnormal m6A modification in breast cancer**

Among all malignant tumours in women, breast cancer has the highest incidence and leads to the highest number of deaths [71, 72]. Although the therapeutic outcomes of early-stage breast cancer are relatively good, treatments for metastasis are not effective [73]. Given the high recurrence and mortality rate, the molecular mechanisms that regulate breast cancer phenotypes need to be carefully delineated and studied to design more effective therapies.

In breast cancer stem cells (BCSCs), ZNF217 has been reported to interact with METTL3 and inhibit the m6A methylation of KLF4 and NANOG, which ultimately leads to high expression of KLF4 and NANOG, thus promoting tumorigenesis [74]. Another report indicated that high m6A modification levels on hepatitis B X-interacting protein (HBXIP) and the overexpression of HBXIP caused by high METTL3 levels accelerate the proliferation of BCSCs [75]. In addition, a study revealed that high levels of m6A modification on MAGI3 lead to premature polyadenylation, switching its functional role from a tumour suppressor gene to a dominant-negative oncogene and ultimately promoting tumorigenesis of breast cancer [31]. The aberrant m6A modifications caused by different mechanisms in breast cancer prove that this modification is related to the occurrence and development of breast cancer.

**Aberrant m6A modification in cervical cancer**

Cervical cancer is one of the most common and destructive gynaecological malignancies [76]. Chemoradiotherapy is the major therapy used to treat cervical squamous cell carcinoma [77]. However, chemoradiotherapy resistance is the major cause of treatment failure. Therefore, it is necessary to further understand the molecular mechanisms underlying chemoradiotherapy resistance and explore novel therapeutic treatments for cervical squamous cell carcinoma (CSCC) [78].

In CSCC, the expression of FTO is significantly higher than that in normal tissues, resulting in lower levels of m6A modification in β-catenin, which causes decreased expression of β-catenin and chemoradiotherapy resistance. The discovery of this mechanism suggests that MA2, a novel small molecular inhibitor of FTO, may increase the chemoradiotherapy sensitivity of CSCC [79].

**METTL3 promotes the translation of oncogenes in human lung cancer**

Lung cancer is one of the most common malignant tumours in humans, causing many deaths every year [80, 81]. The 5-year survival rate of lung cancer patients is still very low despite continuous improvement and progress in the diagnosis and treatment of lung cancer [82, 83]. Non-small-cell lung carcinoma (NSCLC) accounts for 85% of all pathological types of lung cancer [82, 83]. Our attention should be focused on the abnormal molecular biological characteristics of NSCLC to find an effective treatment.

Many articles have reported that abnormal m6A modifications ultimately affect tumour development. However, one report indicated that in lung cancer, METTL3 associates with translation machinery and enhances the translation of target mRNA (RGFR and TAZ) independent of its methyltransferase activity [84]. Another report also indicated that miR-33a inhibits NSCLC cell proliferation by targeting METTL3, which suggests that miR-33a may be a potential molecule for therapy [85]. Moreover, post-translational modification of METTL3 has been revealed. For example, METTL3 is modified by SUMO1, and SUMOylation of METTL3 decreases m6A levels on mRNAs, which ultimately promotes the development of NSCLC [86].
m\textsuperscript{6}A leads to the acceleration of tumour formation
In AML, upregulated m\textsuperscript{6}A modification on MYB, MYC, BCL2, PTEN and SPI1 results in enhancement of the binding capability and translational efficiency of onco-RNA and ribosomes, leading to tumorigenesis [47–50]. Moreover, in hepatocellular carcinoma, the excessive m\textsuperscript{6}A modification of the SOCS2 tumour suppressor gene reduces mRNA stability and accelerates its degradation, which causes tumour progression [60]. In addition, in breast cancer, upregulated m\textsuperscript{6}A modification of HBXIP and MAGI3 results in tumour formation [31]. It is worth noting that excessive modification of MAGI3 leads to premature polyadenylation, switching its function role from that of a tumour suppressor gene to a dominant-negative oncogene, ultimately promoting tumorigenesis [31]. In summary, RNA methylation triggers certain alterations to tumour-specific mRNA behaviour and results in changes in onco-protein expression and biologic activity, thereby accelerating the tumour progression.

m\textsuperscript{6}A contributes to the inhibition of tumour development
In contrast, the aberrant decreased m\textsuperscript{6}A modification levels on target loci can also disrupt normal RNA functions, which in turn restores normal m\textsuperscript{6}A levels on these targets and ideally suppresses tumour formation. The FTO-mediated downregulation of m\textsuperscript{6}A modification levels on ASB2 and RARA leads to the downregulation of these anti-oncogenes via RNA and protein degradation, leading to the promotion of tumorigenesis [47]. In hepatocellular carcinoma, the decreased m\textsuperscript{6}A modification levels on microRNA126 influence its function as a ceRNA and disrupt its regulation of binding capability, thereby triggering the acceleration of tumour development [61].

Similarly, in GSCs, a long non-coding RNA FOX-M1-AS directly binds to FOXM1 mRNA, enhancing the interaction between ALKBH5 and FOXM1 nascent transcripts and giving rise to reduced m\textsuperscript{6}A modification levels and the overexpression of this oncogene [70]. Additionally, decreased m\textsuperscript{6}A modification levels enhance the RNA stability of KLF4 and NANOG and ultimately contribute to tumour formation [74]. In summary, it has been revealed that decreased RNA methylation may participate in tumorigenesis. Therefore, a novel therapeutic strategy may involve tumour suppression via enhanced m\textsuperscript{6}A modification to balance the transcription of these genes.

Conclusion
In summary, an increasing number of studies has shown that aberrant m\textsuperscript{6}A modification is closely related to tumorigenesis, including AML, HCC, GSCs, breast cancer, cervical cancer and lung cancer [50, 60, 70, 75, 79]. Moreover, numerous genes modified by m\textsuperscript{6}A have been revealed to play regulatory roles in tumour formation, such as BCL2, PTEN, SOCS2, FOXM1 and HBXIP [50, 60, 70, 75, 79]. In conclusion, m\textsuperscript{6}A modification is a double-edged sword, over-modification of a target gene by m\textsuperscript{6}A could result in altered RNA splicing and translational capability, leading to the acceleration of cancer formation, whereas the lack of m\textsuperscript{6}A modification at other loci may also contribute to tumorigenesis.

Abnormal levels of m\textsuperscript{6}A methylation may give rise to tumour progression. However, we should not ignore the notion that RNA methylation enzymes influence tumorigenesis in an m\textsuperscript{6}A-independent manner. For example, in lung cancer, METTL3 directly associates with translation machinery and enhances the translation of target mRNA (RGFR and TAZ) independent of its methyltransferase activity [84].

This review updates our knowledge of the aberrant m\textsuperscript{6}A methylation of diverse target loci and discusses its impact on tumour formation. Aberrant levels of m\textsuperscript{6}A modification, such as increased or decreased levels, may alter RNA splicing, RNA-coding capability or onco- or tumour suppressor genes. To discover novel tumour therapies based on the evaluation of m\textsuperscript{6}A modifications, it should be noted that m\textsuperscript{6}A functions as a dual-edged weapon; thus, restoring ideal levels of m\textsuperscript{6}A (rather than simply over-supplementing or over-silencing) holds great significance.

Abbreviations
3′UTRs: 3′ untranslated regions; ADDM19: A disintegrin and metallopeptidase domain 19; ALKBH5: AlkB homologue 5; AML: Acute myeloid leukaemia; ASB2: Anklyrin repeat and SOCS box containing 2; A-to-I: Adenosine-to-inosine; BCL2: B cell leukaemia 2; BCSCs: Breast cancer stem cells; CDKN2A: Cyclin dependent kinase inhibitor 2A; CGSH: Cytokine inducible SH2 containing protein; CSCC: Cervical squamous cell carcinoma; Dnmt3B: DNA methyltransferase 3B; ESCs: Embryonic stem cells; EZH2: Enhancer of zeste 2 polycomb repressive complex 2 subunit; FL(2)id: Female-lethal(2)id; FMR1: Fragile X mental retardation 1; FOXM1: Forkhead box M1; FTO: Fat mass and obesity-associated protein; GSCs: Glioblastoma stem cells; HBXIP: Hepatitis B X-interacting protein; HCC: Hepatocellular carcinoma; HNRNP: Heterogeneous nuclear ribonucleoprotein; ID4: Inhibitor of DNA binding 4; IGFB2Ps: Insulin-like growth factor 2 mRNA-binding proteins; IL-7: Interleukin 7; Ilm4: Inducer of meiosis 4; KARF: Karyogamy protein 4; KIF4: Kif22; KR: Kruppel like factor 4; KLF4: Kruppel like factor 4; LRPPRC: Leucine rich pentatricopeptide repeat containing; m\textsuperscript{6}A: N6-methyladenosine; MAGI3: Membrane associated guanylate kinase; MAGJ3: Membrane associated guanylate kinase, WW and PDZ; MALAT1: Metastasis-associated lung adenocarcinoma transcript 1; MAT2A: Methionine adenosyl transferase 2A; METTL14: Methyltransferase-like 14; METTL6: Methyltransferase-like protein 16; METTL3: Methyltransferase-like 3; MYB: Myeloblastosis oncogene; MYC: Myc; Metastasis-associated lung adenocarcinoma transcript 1; Retinoic acid receptor alpha; RBM15: RNA binding motif protein 15; SAM: S-adenosylmethionine; SEDTb8: SET domain bifurcated 1; SOCS2: Suppressor of cytokine signalling 2; SOX2: Sex determining region Y box 2; SSCLs: Spermatogonial stem cells; STAT5: Activator of transcription 5; SUIM01: Small ubiquitin-like modifier 1; SVJ39H1: Suppressor of variation 3–9 homolog 1; TIF-2: Tissue factor pathway inhibitor 2; WAP: Wilms tumour 1-associated protein; YTH: YTS21-B homology; ZC3H13: Zinc finger CCHC-type containing 13, ZFP217: Zinc finger protein 217, ZNF217: Zinc finger protein 217.
Funding
This work was supported by the Natural Science Foundation of China grant (18102366, 81402258, 81570884), the Scientific Research Program of National Health and Family Planning Commission of China (201402014), the ShuGuang Project of Shanghai Municipal Education Commission and Shanghai Education Development Foundation (14SG18), and the Science and Technology Commission of Shanghai (17DZ2260100).

Authors’ contributions
RJ provided direction and guidance throughout the preparation of this manuscript. SW collected and interpreted studies and was a major contributor to the writing and editing of the manuscript. PC reviewed and made significant revisions to the manuscript. RJ assisted in the revision of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 20 February 2018 Accepted: 29 June 2018
Published online: 21 July 2018

References
1. Machnicka MA, Milanowska K, Osman Oglou O, Purta E, Kurkowska M, Osman Oglou O, Purta E, Kurkowska M, et al., et al. Recognization of RNA N6-methyladenosine by the eukaryotic YTH domain. Proc Natl Acad Sci U S A. 2015;112(16):E2195–204. 2. Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger RNA from N6-adenosine methyltransferase of MTLL16. J Biol Chem. 1994;269(26):17697–704.
3. Wei CM, Gershowitz A, Moss B. Methylated nucleotides block 5′-terminal 7-methylguanosine in cap structures. J Biol Chem. 1979;254(9):5557–67.
4. Kane SE, Beemon K. Precise localization of m6A in Rous sarcoma virus RNA by the eukaryotic YTH domain. Proc Natl Acad Sci U S A. 2015;112(16):E2195–204.
5. Sommer S, Salidett-Georgieff M, Bachenheimer S, Darnell JE, Furuichi Y, et al. The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science. 2007;318(5853):469–72.
6. Deng X, Chen K, Luo GZ, Weng X, Ji Q, Zhou T, He C. Widespread occurrence of N6-methyladenosine in bacterial mRNA. Nucleic Acids Res. 1975;4(4):379–86.
7. Kennedy TD, Lane BG. Wheat embryo ribonucleates. XIII. Methyl-substituted methyladenosine and 5′-terminal dinucleotide sequences in bulk poly(A)-rich RNA from imbibing wheat embryos. Can J Biochem. 1979;57(6):927–31.
8. Bokar JA, Rath-Shambaugh ME, Ludiviczak R, Narayan P, Rottman F. Characterization and partial purification of RNA N6-adenosine methyltransferase from HeLa cell nuclei. J Biol Chem. 1994;269(26):17697–704.
9. Bokar JA, Shambaugh ME, Polayes D, Natera AG, Rottman FM. Purification and cDNA cloning of the AdoMet-binding subunit of the human RNA (N6-adenosine)-methyltransferase. RNA. 1997;3(11):1233–47.
10. Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L, Jia G, Yu M, Lu Z, Deng X, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014;10(2):93–5.
11. Schwartz S, Mumbach MR, Jovanovic M, Wang T, Maciag K, Bushkin GG, Mentpin P, Ter-Ovanesyan D, Habib N, Cacchiarelli D, et al. Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5′ sites. Cell Rep. 2014;8(1):284–96.
12. Visvanathan A, Somasundaram K. mRNA traffic control reviewed: N6-methyladenosine (m6A) takes the driver’s seat. Bioessays. 2018;40(1).
37. Agullo F, Zhang F, Sancho A, Fidalgo M, Di Cecilia S, Vashishth A, Lee DF, Chen CH, Rengasamy M, Andino B, et al. Coordination of m(6)A mRNA methylation and gene transcription by ZFP217 regulates pluripotency and reprogramming. Cell Stem Cell. 2015;17(6):689–704.

38. Haussmann IU, Bodl Z, Sanchez-Moran E, Morgan NP, Archer N, Fray RG, Soller M. m(6)A potentiates Sxl alternative pre-mRNA splicing for robust Drosophila sex determination. Nature. 2016;540(7632):301–4.

39. Lin Z, Hsu PJ, Xing X, Fang J, Lu Z, Zou Q, Zhang KJ, Zhang X, Zhou Y, Zhang T, et al. Mettl3–Mettl4-mediated mRNA N6-methyladenosine modulates murine spermatogenesis. Cell Rep. 2017;27(10):1216–30.

40. Li HB, Tong J, Zhu S, Batista PJ, Duffy EE, Zhao J, Ballis W, Cao G, Kroeplin L, Chen Y, et al. m(6)A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways. Nature. 2017;548(7667):338–42.

41. Penalva LO, Ruiz MF, Ortega A, Granadino B, Vicente L, Segarra C, Valcarcel J, Sanchez L. The Drosophila fl(2)cd gene, required for specific splicing of Sxl and tra pre-mRNAs, encodes a novel nuclear protein with a HQ-rich domain. Genetics. 2000;155(1):29–39.

42. Niessen M, Schneider R, Nolteger R. Molecular identification of virlizer, a gene required for the expression of the sex-determining gene sex-lethal in Drosophila melanogaster. Genetics. 2001;157(2):679–88.

43. Horiiuchi K, Kamawara T, Iwanari H, Ohashi R, Naito M, Kodama T, Hamakubo T. Identification of Wilms' tumor 1-associated protein complex and its role in alternative splicing and the cell cycle. J Biol Chem. 2013;288(46):33292–302.

44. Fang NN, Chan GT, Zhu M, Comyn SA, Persaud A, Deshaies RJ, Rotin D, Gsponer J, Marcucci G, Mrozek K, Bloomfield CD. Molecular heterogeneity and potential therapeutic targets. Nat Genet. 2015;47(5):505–10.

45. Horiuchi K, Kawamura T, Iwanari H, Ohashi R, Naito M, Kodama T, Niessen M, Schneiter R, Nothiger R. Molecular identification of virilizer, a sex determination gene in Tribolium castaneum. J Biol Chem. 2001;276(50):48761–7.

46. Li Z, Weng H, Su R, Weng X, Zhuo Z, Li C, Huang H, Nachtegaale S, Dong L, Hu C, et al. FTO plays an oncogenic role in acute myeloid leukemia as a (m)6A-dependent translation control. Nature. 2017;552(7683):126–30.

47. Cheng CL, Lee JM, Wong CC, Cheung OF, Chan CY, Tung EK, Ching YP, Ng IO, Wong CM. Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES2. J Hepatol. 2015;67(4):558–69.

48. Chen M, Wei L, Law CT, Tsang FH, Shen J, Cheng CL, Tsang LH, Ho DW, Chiu DK, Lee JM, et al. RNA N6-methyladenosine methyltransferase METTL3 promotes liver cancer progression through YTHDF2-dependent post-transcriptional silencing of SOCS2. Hepatology. 2017.

49. Ma JZ, Yang F, Zhou CC, Liu F, Yuan JH, Wang F, Wang TT, Xu QZ, Zhou WP, Sun SH. METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N6-methyladenosine-dependent primary MicroRNA processing. Hepatology. 2017;65(2):529–43.

50. Johnson DR, O'Neill WP. Global warming in the United States before and during the 1941-2006 period. J Geophys Res. 2018;103(7):359–64.

51. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.

52. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature. 2009;452(7185):396–401.

53. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glial stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7112):756–60.

54. Godlewski J, Newton HB, Chiocca EA, Lawler SE. MicroRNAs and glioblastoma; the stem cell connection. Cell Death Differ. 2010;17(2):221–8.

55. Sundar SJ, Hsieh JK, Manjila S, Lathia JD, Sloan A. The role of cancer stem cells in glioblastoma. Neurosurg Focus. 2014;37(6):E6.

56. Allegra A, Abonc A, Penna G, Innao V, Geraec D, Rotondo F, Musolino C. The cancer stem cell hypothesis: a guide to potential molecular targets. Cancer Investig. 2013;31(2):470–95.

57. Cui Q, Shi H, Ye P, Li L, Qu Q, Sun G, Sun G, Lu Z, Huang Y, Yang CG, et al. m(6)A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells. Cell Rep. 2017;18(11):2622–34.

58. Zhang S, Zhao BS, Zhou A, Lin K, Zheng S, Lu Z, Chen Y, Saloman EP, Xie K, Bogler O, et al. m(6)A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program. Cancer Cell. 2017;31(4):591–606. e596.

59. DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A. International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomark Prev. 2015;24(10):1495–506.

60. DeSantis CE, Ma J, Godling Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017; racial disparity in mortality by state. CA Cancer J Clin. 2017;67(6):439–49.

61. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(Suppl 3):20–9.

62. Zhang C, Zhi WM, Lu H, Samanta D, Chen I, Gabrielsson E, Semenza GL. Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells. Oncotarget. 2016;7(46):74527–42.

63. Cai X, Wang X, Cao C, Gao Y, Zhang S, Yang Z, Liu Y, Zhang X, Zhang W, Ye L. HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g. Cancer Lett. 2018;415:1–11.

64. Small WJ, Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshkin LR, Viswanathan AN, et al. Cervical cancer: a global health crisis. Cancer. 2017;123(13):2404–12.

65. Verma J, Monk BJ, Wolfson AH. New strategies for multimodality therapy in treating locally advanced cervix cancer. Semin Radiat Oncol. 2016;26(4):344–8.

66. Tewari KS, Monk BJ. New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy. Clin Cancer Res. 2014;20(21):5349–58.

67. Zhou S, Bai ZL, Xia D, Zhao ZJ, Zhao R, Wang YY, Zhe H. FTO regulates the chemo-radiotherapy resistance of cervical squamous cell carcinoma (SCC) by targeting beta-catenin through mRNA demethylation. Mol Carcinog. 2018;57(5):590–7.
80. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–94.

81. Hussain S. Nanomedicine for treatment of lung cancer. Adv Exp Med Biol. 2016;890:137–47.

82. Araz O, Ucar EY, Meral M, Yalcin A, Acemoglu H, Dogan H, Karaman A, Aydin Y, Gorguner M, Akgun M. Frequency of class I and II HLA alleles in patients with lung cancer according to chemotherapy response and 5-year survival. Clin Respir J. 2015;9(3):297–304.

83. Latimer KM, Mott TF. Lung cancer: diagnosis, treatment principles, and screening. Am Fam Physician. 2015;91(4):250–6.

84. Lin S, Choe J, Du P, Triboulet R, Gregory RI. The m(6)A methyltransferase METTL3 promotes translation in human cancer cells. Mol Cell. 2016;62(3):335–45.

85. Du M, Zhang Y, Mao Y, Mou J, Zhao J, Xue Q, Wang D, Huang J, Gao S, Gao Y. MiR-33a suppresses proliferation of NSCLC cells via targeting METTL3 mRNA. Biochem Biophys Res Commun. 2017;482(4):582–9.

86. Du Y, Hou G, Zhang H, Dou J, He J, Guo Y, Li L, Chen R, Wang Y, Deng R, et al. SUMOylation of the m6A-RNA methyltransferase METTL3 modulates its function. Nucleic Acids Res. 2018;46(10):5195–208.